Blurbs

Jefferies Sticks to Their Buy Rating for Karuna Therapeutics (KRTX)

Jefferies analyst Chris Howerton maintained a Buy rating on Karuna Therapeutics (KRTXResearch Report) yesterday and set a price target of $284.00. The company’s shares closed yesterday at $261.01.

According to TipRanks, Howerton is an analyst with an average return of -9.9% and a 36.16% success rate. Howerton covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Celldex, and Karuna Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Karuna Therapeutics with a $278.69 average price target, a 6.77% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $274.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $278.25 and a one-year low of $92.26. Currently, Karuna Therapeutics has an average volume of 489.6K.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KRTX in relation to earlier this year. Earlier this month, James Healy, a Director at KRTX bought 32,500.00 shares for a total of $520,000.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.

Read More on KRTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More